David, NWBio does not have any control of the time it takes for the peer-review process, nor do they have any control over when the DCVax-L Phase III clinical trial journal article is published. NWBio is not in control of when TLD and the journal article will be released.
But, what NWBio could control was the build out of Sawston and getting it GMP licensed with the MHRA. So, NWBio did not waste time complaining about what they couldn’t control, but decided to focus on what they could control. Now we as NWBO shareholders are much closer to getting DCVax-L approved in the US, UK, Canada, Germany and the rest of the EU.
Market Data 
Markets 
AI
